MRI vendor Fonar of Melville, NY, has received a patent for MRIbreast scanning of multiple patients, the company reported thismonth. The technique could be used with Fonar's new Quad seriesof MRI magnets, which are open on all four sides and can be
MRI vendor Fonar of Melville, NY, has received a patent for MRIbreast scanning of multiple patients, the company reported thismonth. The technique could be used with Fonar's new Quad seriesof MRI magnets, which are open on all four sides and can be fittedwith up to four patient beds, with a screen between the patientsas they are shuttled through the magnet.
Fonar hopes that the multiple-bed configuration will increasethe throughput and reduce the cost of breast MRI scanning enoughto make it competitive with conventional x-ray mammography. Theconfiguration allows as many as 10 patients to be scanned in anhour, according to Fonar.
Fonar has aggressively defended other MRI patents against whatit claims are infringements by other vendors. It has settled claimsagainst Hitachi and Philips and is involved in litigation withGE, Siemens, and Toshiba.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.